In newborn errors of metabolism, biomarkers are urgently needed for disease screening, diagnosis, and monitoring of therapeutic interventions. This article describes a 2-step approach to discover metabolic markers, which involves (1) the identification of marker candidates and (2) the prioritization of them based on expert knowledge of disease metabolism. For step 1, the authors developed a new algorithm, the biomarker identifier (BMI), to identify markers from quantified diseased versus normal tandem mass spectrometry data sets. BMI produces a ranked list of marker candidates and discards irrelevant metabolites based on a quality measure, taking into account the discriminatory performance, discriminatory space, and variance of metabolites' concentrations at the state of disease. To determine the ability of identified markers to classify subjects, the authors compared the discriminatory performance of several machine-learning paradigms and described a retrieval technique that searches and classifies abnormal metabolic profiles from a screening database. Seven inborn errors of metabolismphenylketonuria (PKU), glutaric acidemia type I (GA-I), 3-methylcrotonylglycinemia deficiency (3-MCCD), methylmalonic acidemia (MMA), propionic acidemia (PA), medium-chain acyl CoA dehydrogenase deficiency (MCADD), and 3-OH longchain acyl CoA dehydrogenase deficiency (LCHADD)-were investigated. All primarily prioritized marker candidates could be confirmed by literature. Some novel secondary candidates were identified (i.e., C16:1 and C4DC for PKU, C4DC for GA-I, and C18:1 for MCADD), which require further validation to confirm their biochemical role during health and disease. (Journal of Biomolecular Screening 2006:90-99) Key words: biomarker discovery, disease classification, similarity query processing, tandem mass spectrometry, metabolic disorders 90 www.sbsonline.org
INTRODUCTION

R ECENT ADVANCES IN MODERN SCREENING TECHNOLOGIES
such as tandem mass spectrometry (MS/MS) have made it possible to separate and identify small molecules based on their masses from samples of a biofluid such as blood serum or urine. By using appropriate internal standards, the concentration of a molecule in fluid can be measured with great precision because the accuracy and sensitivity of the instrumentation are high. [1] [2] [3] [4] MS/MS provides high-throughput data for the discovery of diagnostic markers, which is very relevant to the understanding of how metabolic disorders manifest. In particular, abnormal concentrations of metabolites may indicate erroneous metabolic reactions and may reflect the actual functional state of a patient. So biomarkers are important tools for disease screening and early diagnosis. [5] [6] [7] [8] [9] [10] [11] In this work, we delineated a 2-step approach to biomarker discovery, which involves (1) the identification of markers and (2) the prioritization of identified subsets of marker candidates. For step 1, we developed a new algorithm, the biomarker identifier (BMI), to identify disease state metabolites from quantified 2-class (diseased vs. normal) MS data sets. BMI returns a ranked list of marker candidates qualified by a suitable score measure. In step 2, marker candidates were prioritized based on literature knowledge of disease metabolism. Because biomarkers are those features that allow a well-done classification, we compared various classifiers to estimate their prognostic and diagnostic power. High-throughput MS/ MS data, as generated in newborn screening programs, for example, are too voluminous and complex to catalog by hand, so they must be stored and managed in modern database systems. A query model was introduced that uses a simple similarity measure based on BMI score-weights to search and classify abnormal metabolic profiles from the database.
To see if we could generalize results across experiments, MS/ MS data of 7 severe inborn errors of metabolism and healthy control subjects were investigated. A brief description of the examined disorders regarding their enzyme defects, established diagnostic markers, and their natural history is summarized in Table 1 , which helped us to prioritize and confirm marker candidates according to the established biochemical knowledge. [12] [13] [14] [15] [16] [17] [18] 
MATERIALS AND METHODS
Research Data
Experiments were performed on 2-class (diseased vs. normal) data sets extracted from our MS/MS research database (DB). The data set comprises 545 data from 7 inborn errors of metabolismthat is, 1 amino acid disorder (phenylketonuria [PKU], n = 263), 4 organic acid disorders (glutaric acidemia type I [GA-I], n = 27; 3methylcrotonylglycinemia deficiency , n = 43; methylmalonic acidemia [MMA], n = 50; propionic acidemia [PA], n = 50), 2 fatty acid oxidation disorders (medium-chain acyl CoA dehydrogenase deficiency [MCADD], n = 52; 3-OH longchain acyl CoA dehydrogenase deficiency [LCHADD] , n = 60), and 5099 normals. The DB is organized in the form of a set of tuples T DB = {(c j , m) | c j ∈ C, m ∈ M}, where c j is the class label of the collection C of investigated disorders and controls, and M = {m | m 1 , . . ., m n } is the given set of metabolite concentrations in µmol/ L. The symbol ∈ means "belong to." In detail, M consists of 29 acyl-carnitines (i.e., C0, C2, C3, C4, C5, C6, C8, C10, C12, C14, C16, C18, C5:1, C10:1, C14:1, C16:1, C18:1, C10:2, C14:2, C18:2, C5OH, C14OH, C16OH, C16:1OH, C18:1OH, C4DC, C5DC, C6DC, C12DC) and 14 amino acids (i.e., ALA, ARG, ARGSUC, CIT, GLU, GLY, MET, ORN, PHE, PYRGLT, SER, TYR, VAL, and XLE) in all 43 metabolites. The used abbreviations for amino and fatty acids match the IUPAC/IUBMB nomenclature (http://www.chem.qmul.ac.uk/iupac).
Biomarker identification using BMI
The basic idea of the paradigm BMI was to make use of a 2-step data-processing procedure to discern the discriminatory attributes between 2 classes of interest (i.e., the full set of MS traces of each metabolite profile from diseased patients against another set from normal people). 19 Both steps include the following:
1. Identification of marker candidates and deletion of irrelevant metabolites from a given metabolite collection M. For that task, 3 measures describing erroneous metabolic reactions at the level of concentration changes in fluid were taken into account to develop a quality (score) measure for the selection of potential markers candidates. It defines (a) the discriminatory performance of each metabolite m ∈ M determined by a machine-learning paradigm, (b) the extent of discriminatory space between normal and disease state concentration values, (c) the variance of measured abnormal metabolite concentrations at the state of disease. 2. Ranking of the selected metabolites. A list of marker candidates ranked by the size of calculated score values is returned.
The following definitions are required: Let DS be a 2-class MS data set organized as a set of tuples m ∈ M}, where c 1 is the class label of a metabolic disorder, c 2 is the control class, and M is the given set of metabolite concentrations.
We used logistic regression analysis (LRA) to determine the discriminatory performance of each metabolite m ∈ M. 20 LRA, a learning method that constructs a separating hyperplane between the 2 data sets, assigns class membership by a probability measure in the form of P(y = 1) = 1/[1 + exp(-z)], where z = a 0 + a 1 x is the logit of the classification model. Here, x is the input variable, the metabolite concentration, and a 0 , a 1 are the logit coefficients that have to be learned by the method. The discriminatory threshold t s between both classes can be explicitly calculated from the coefficients a 0 and a 1 and is defined in equation (1):
(
This concentration threshold separating both classes corresponds with a probability of P(y = 1) = 0.5, the measure that determines class membership. Thus, a P-value ≥ 0.5 or < 0.5 clearly assigns a test subject. We do need the parameter t s later for matching metabolic profiles (see Similarity Query Processing).
The discriminatory performance of each metabolite m was calculated as product of the true positive (TP) rates of class c 1 and c 2 :
To emphasize the small prevalence of inborn errors in a real screening population, a~100-fold larger group of normals compared to disorder class was examined. This unbalance of class size is necessary to avoid an overestimation of TP rates in the control class. 21 Because TPc 2 rates (specificities) ≥ 99.6% were computed in all study experiments, the performance measure TP* is predominantly determined by the value of the TPc 1 rate (sensitivity) describing the fraction of correctly classified diseased subjects. TP* is thus more sensitive than overall classification accuracy (= correctly classified subjects in both classes/all subjects), which does not reflect the unbalancedness of classes.
The range of discriminatory space between normal and disease state concentrations of m is estimated by the parameter ∆ diff , which approximates the mean distance between both data distributions:
where x c i is the mean metabolite concentration in class c i . ∆ ≥ 1 denotes a concentration enhancement, ∆ < 1 a decrease of concentration in fluid. The score value s i ∈ S qualifying a processed metabolite m i ∈ M is thus defined as s TP
where λ is a scaling factor, and CV defined as σ/x is the coefficient of variation at the state of disease. We set λ = 10 by default because then score values range between 1 and~1000, which is of practical advantage. x is the mean value and σ the standard deviation of concentration values calculated from disorder class c 1 . S denotes the collectivity of identified marker candidates represented by their score values. Finally, a ranked list of marker candidates, m i ⊆ M, is returned by BMI. Irrelevant metabolites, m j ⊆ M (m i ∪ m j = M), are discarded from M using a cutoff score value |s| < 5 by default.
The algorithm boxed above is briefly sketched as pseudo-code helpful for software implementation.
To quantify the information content of a disease-specific score set S, the measure s D was introduced: Input Two-class data set DS organized as a set of tuples T c1 and T c2 T c1 := c 1 , m 1 , m 2 , . . ., m n ; T c2 := c 2 , m 1 , m 2 , . . ., m n ; S = { } Output:
Ranked list of marker candidates S := s 1 , s 2 , . . ., s m List of discriminatory thresholds TS := t s1 , t s2 , . . ., t sm Algorithm:
BMI (Data set DS, Ranked list S, Threshold list TS) for i from 1 to n do m i := DS.get(i) TP i * := Discriminatory performance of m i determined by the learning method; ts i := Discriminatory threshold of m i determined by the learning method; ∆diff i := Extent of discriminatory space of m i ; CV i := Coefficient of variation of class C 1 ;
In addition, the information content of an individual metabolic expression * s D can be expressed similar to equation (5), but the parameter ∆ diff defined in equation (3) must be replaced by
where m denotes the measured metabolite concentrations of a single subject. This measure is very helpful to assess gradual expressions of affected individuals (e.g., strong or mild form) compared to the overall picture of a disease.
To assess the quality of attribute selection, we benchmarked BMI with 2 filter-based feature selection techniques, producing an attribute ranking equal to our algorithm: (1) information gain (IG), which computes how well a given feature separates data by expecting a reduction of entropy, and (2) relief, which is an exponent of a correlation-based selection method coupling an applicative correlation measure with a heuristic search strategy. 21, 22 
Classification
The performance of identified marker candidates is determined on their ability to classify subjects. Classifiers are built from MS data with known classes, which comprise a training set in the form of a set of tuples TR = {(c j , m) | c j ∈ C, m ∈ M}. Classifiers can then be applied to a test set consisting of a set of tuples TS = {m | m ∈ M} to predict the class for each subject. In this study, we compared several popular methods-that is, LRA, k-NN, naive Bayes, support vector machines (SVM), and artificial neural networks (ANN), which are used for classifying metabolomic/proteomic data. 21, [23] [24] [25] [26] For general information on classification algorithms, see, for example, Mitchell, 27 Cristianini and Shawe-Taylor, 28 Shawe-Taylor and Cristianini, 29 Gelman et al, 30 and Raudys. 31 We examined classification accuracy of classifiers with respect to (w.r.t.) a 2-class problem, at which 2 views of data sets were considered: (1) disorder versus control class and (2) disorder versus normals, including data sets of the remaining study disorders, respectively. The latter grouping, which better reflects a real screening population, is warranted to estimate classification accuracy for disorders represented by not disease-specific diagnostic markers. Discriminatory performance of classifiers was denoted by the following established measures: recall (sensitivity, specificity), precision (positive predicted value [PPV], negative predicted value [NPV]), and accuracy. 32 To avoid an overestimation of results, stratified 10-fold crossvalidation was applied to classifiers and feature selection paradigms BMI, IG, and relief because disorder data sets were too small to be separated into representative training and test sets.
Here, data sets are randomly divided into 10 sets with approximately equal size and class distributions to obtain validated experimental results. 32
Similarity query processing
We propose a simple retrieval technique to search and classify subjects from DB. For matching MS profiles, a square distance measure based on BMI score-weights was introduced. The following definitions are required:
Let DB* be a MS/MS screening database in the form of a set of unclassified tuples T DB
be the query model of an abnormal metabolic profile given by the score set S and its corresponding set of discriminatory thresholds TS, as determined by BMI.
For matching T DB * with the query model Q D , the following similarity measure r D is computed:
Here, the decision function δ identifies those metabolites in T DB * (δ = 1) whose concentration values exceed or fall below the discriminatory threshold t s and replaces them by the corresponding scores s ∈ Q D . Because maximal metabolic similarity fits to a maximal value of r D , the best-ranked hits according to maximal value of r D are returned as the query result.
RESULTS
Biomarker identification and prioritization
We applied BMI to the 7 two-class data sets (PKU, GA-I, 3-MCCD, MMA, PA, MCADD, LCHADD vs. normals), as extracted from our research database. Figure 1 exemplifies all analytical steps for calculating score value s C8 (i.e., octanyl-carnitine [C8]), the primary diagnostic marker for MCADD. Values of discriminatory parameters t s and TP*, extent of discriminatory space ∆ diff , and coefficient of variation CV are shown explicitly. More specifically, the discriminatory threshold of C8 was computed more than 15 standard deviations above the controls' mean (t s = 0.62 µmol/L); its discriminatory performance was close to 1.0 (TP* = 0.96). Furthermore, the higher variance of measured concentrations in the MCADD group led to a twice as large CV value (0.78) compared to the control class (CV = 0.36). A 62-fold elevation of mean C8 concentration at the state of disease (∆ diff = 61.9) returned a strongly elevated score value s C8 of 914(!), the largest one identified in this study. Table 2 summarizes the identified marker candidates of all investigated inborn errors. Interpreting the computed score values, it is conspicuous that each disorder is characterized by at least 1 hallmark metabolite, which outperforms the others significantly. These key metabolites showing scores uniformly above 100 corresponded exactly with the established primary diagnostic markers as described in the literature (see also Table 1). So we prioritized metabolites with score values |s| ≥ 100 as primary markers, score values between 20 ≤ |s| < 100 as secondary markers, and score values |s| < 20 as tertiary markers. Categorized marker subsets are presented in Table 3 . The prioritization into secondary and tertiary markers appears to be useful to distinguish between further promising marker candidates, of which the latter group may be more closely associated with secondary effects of metabolism. A fourth category was required to be introduced because several marker candidates-that is, decanoyl-carnitine (C10), hexadecanoyl-carnitine (C16), decenoyl-carnitine (C10:1), arginine (ARG), and glutamate (GLU)-appeared together in nearly all 7 study disorders representing the group of not diseasespecific markers. For more details, see Tables 2 and 3. By way of example, Figure 2 displays the ranked list of selected metabolites for MCADD, a fatty acid oxidation defect, which leads to an accumulation of short-and medium-chain fatty acids and, in turn, to a decrease of cell energy metabolism. Indeed, the first 3 candidates-C8, C10:1, and C10-fit well to the biochemical knowledge, followed by a group of not disease-specific metabolites. Interestingly, C18:1-by our classification, defined as a secondary marker-appeared before C6 in ranking, a further established (secondary) diagnostic metabolite. Because C10:1, which is metabolized by 4 β-oxidation cycles of oleyl-carnitine (C18:1), is a product of a metabolic reaction in the fatty acid metabolism, C18:1 is qualified to become a novel secondary marker. In addition, Figure 2 depicts the information content of the full MCADD marker score set ( s MCADD = 939) supplemented by 2 examples of a strong ( * s MCADD = 2008) and a mild ( * s MCADD = 467) expression. This measure may be helpful to assess individual metabolic ex-pressions and to bring them into agreement with the patients' therapeutic management.
We benchmarked BMI with 2 popular feature subset selection methods. Figure 3 demonstrates these findings, again exemplified for MCADD. IG returned a quite similar metabolite ranking com- s D denotes the information content of a given score set S with respect to disorder D. Metabolites with score values |s| < 5 were deleted by BMI. A positive score value indicates an abnormal increase, and a negative score indicates a decrease of metabolite concentration in fluid. For definitions of abbreviations, see Table 1 . pared to BMI, whereas relief's ranking differed significantly from both methods BMI and IG. Although IG and relief produced a ranked list of attributes, they lacked the ability to differ clearly between primary and secondary/tertiary markers as BMI did. In particular, MCADD's diagnostic key marker C8 did not stand out significantly from the others in both approaches. For instance, C8's IG was only 6.8% above that of C10:1, whereas C8's BMI score outperformed C10:1 more than 5 times (+528%). Relief even ranked C8 after C16 and C18:1-both metabolites showed slightly decreased concentration values-which does not clearly reflect C8's high discriminatory performance, its superior concentration enhancement, and moderate coefficient of variation at the state of disease.
Disease classification
The performance of metabolic markers is determined on their ability to classify subjects. So we compared 5 machine-learning paradigms (i.e., LRA, k-NN, naive Bayes, SVM, and ANN) according to their discriminatory power and tried to assess their applicability for disease screening and diagnostics. In this study, classifiers were basically applied to 2-class data sets testing classification accuracy of (1) primary markers alone; (2) primary, secondary, and tertiary markers, excluding not disease-specific ones; and (3) the full BMI marker set. We designed both classes of interest as aforementioned: (a) disorder versus controls and (b) disorder versus controls, including the remaining study diseases. Our experiments clearly indicated increasing classification accuracy when considering the order of primary → primary + secondary + tertiary → all markers as classifiers' inputs and little differences in accuracy when comparing data sets (a) and (b). However, 2 exceptions in experimental data (i.e., MMA and PA) appeared. MMA and PA belong to the group of organic acid disorders and are characterized by the identical primary diagnostic marker propionylcarnitine (C3). Table 4 points out this situation, considering as example MMA. Our results revealed that sensitivity of all tested classifiers dropped dramatically, particularly if classification models were solely built on the primary markers-for example, LRA: 80% (a) ↓ 19% (b), SVM (linear): 66% (a) ↓ 2% (b), or ANN: 82% (a) ↓ 20% (b). Testing the full marker set, classification accuracy could be further enhanced, but accuracy did not achieve values of data set (a). Analyzing the behavior of classifiers on MMA data in more detail, ANN yielded the best classification accuracy w.r.t. both data sets. Although both classes are strongly unbalanced in size, LRA, SVM, and k-NN showed promising results as well. Nevertheless, little differences in accuracy were observed, which primarily arise from the strengths and weaknesses of the target learning algorithm, along with the characteristics of the analyzed data. Naive Bayes, which classifies a subject based on the probability of each class given the subject's feature variables, returned the most unbalanced classification results, indicated by a too-large fraction of false-negative cases. This minimizes PPV on the full marker set dramatically (68.6% data set (a), 13.5% data set (b)), which is undesirable for disease screening. 
Biomarker Discovery and Classification on MS/MS Data
FIG. 3.
Ranked lists of metabolites are shown using the following filter paradigms: information gain (IG) and relief. The first 11 metabolites are depicted to be comparable with the biomarker identifier (BMI). Black bars indicate the established diagnostic metabolites in MCADD (see Table 1 ).
Abnormal metabolic profile retrieval
Similarity query processing on a large screening DB enables the user to search and classify subjects highly related to a requested metabolic profile. Figure 4 illustrates the first 100 hits of a MMA query on our research DB graphically. We performed 2 requests using query models based on the full BMI marker set and, respectively, the disease-specific subset and determined classification accuracy of delivered hits. Surprisingly, the first 41 hits (left to arrow 1 in the figure) represented a very homogeneous group of MMA cases if the similarity measure r MMA was computed based on the disease-specific markers. This group demonstrated a TP rate of 74%, which was close to that of the best classifier (ANN, 78%), and contained only a small number of wrongly assigned PA cases (9.8%). A slight drop-off of similarity measure r MMA in turn indicated the beginning of a second, homogeneous group of 42 PA plus 4 MMA cases. The TP rate for PA was 84%. So, 2 groups of related metabolic profiles could be separately delivered from 1 request showing a high degree of homogeneity with high classification accuracy. Otherwise, a request based on all marker candidates returned 1 mixed cohort of MMA and PA cases, with a continuous decay of r MMA measure approaching arrow 2. This result is surprising and can be explained by strongly differing r D values of both marker sets: r MMA = 202 versus r PA = 266 for the full set and r MMA = 262 versus r PA = 163 for the disease-specific set, respectively. A 2 times higher difference of the r D measure in the latter set led, thus, to a better separation of both cohorts. DB requests for the remain-ing disorders were unproblematic because the query model Q D differed significantly from each other. Classifiers were separately tested on the disease's primary, secondary, and tertiary markers, as well as the full marker set as identified by biomarker identifier (BMI). Part (a) shows classification accuracy when testing classifiers on a 2-class data set of methylmalonic acidemia (MMA) cases versus healthy controls, and part (b) depicts findings examined on the data set of MMA cases versus controls, including the remaining study disorders. Classification results are given in percentages. Specificities for all experiments were uniformly ≥ 99.6%. We tested logistic regression analysis (LRA), unweighted 1-NN and 5-NN with an Euclidean distance function, naive Bayes, standard SVM (linear) and SVM with polynomial (degree 2) and Gaussian radial basis (RBF) kernels using a cost factor of 100, and a 3-layer (input-hidden-output) ANN using delta rule and back-propagation, 500 epochs to train trough, and a learning rate of 0.3. NN = nearest neighbor; ANN = artificial neural network; SVM = support vector machines; PPV = positive predictive value. 
DISCUSSION
Recent publications on disease classification using data generated by mass spectrometry have mainly focused on identifying biological markers in biofluids to distinguish between disease and normal samples. 21, [23] [24] [25] [26] 33 In particular, at the state of disease, a novel marker may be an indicator for an abnormal metabolic reaction, which is relevant to the understanding of the biochemical cause behind it. Methods used to identify biomarkers in metabolic/ proteomic data include, for example, T-statistics, filter-based feature selection paradigms, classification methods such as decision trees, genetic algorithms, or artificial neural networks. [8] [9] [10] 21, 34, 35 In this work, we developed BMI, a new supervised feature selection paradigm applied to high-dimensional, quantified diseased-versus-normal MS data sets. BMI combines 3 aspects that are relevant for abnormal metabolic reactions at the level of concentration changes in fluid: discriminatory performance, extent of discriminatory space, and variance of concentration values at disease state. Based on these measures, BMI computes a quality criterion that selects the most relevant and discards all irrelevant metabolites from a given metabolite set. The cutoff for deletion (|s| < 5) is suggested because scores below 5 are characterized by insignificant TP* values < 0.15 and slight ∆ diff measures < 2.5, respectively. However, the cutoff parameter is adjustable, which enables the user to select or separate the 3 proposed marker categories. We used LRA for BMI's classification step because it returns the class discriminatory threshold as calculated from the model's logit explicitly. This parameter is essential to formulate the matching rule for numerical data to perform similarity requests of metabolic profiles on DB. However, machine-learning paradigms such as k-NN or neural networks enable a well-done classification, so they can alternatively be used for BMI's classification step, but they lack an easy description of the threshold in terms of the original attributes. Poor classification results on the 1-dimensional data revealed SVM and naive Bayes indicated by highly unbalanced TP rates (cf. Table 4 ). We benchmarked BMI with 2 established filterbased feature selection paradigms, and BMI scored absolutely well. As aforementioned, IG returned a ranking result similar to BMI but did not allow a convincing prioritization, particularly between primary and secondary marker candidates. Relief came off worse because its heuristic takes into account the usefulness of attributes for class prediction along with the level of intercorrelation among them. BMI was developed to better address the issue of biochemical alteration of metabolites in fluid, so that entropy-based or correlation-based approaches are second choice because they do not optimally reflect the characteristics of given MS data structures at disease state.
We prioritized marker candidates according to the proposed scheme of primary, secondary, and tertiary markers. All identified primary and some secondary markers were able to be confirmed by literature association to disease biochemistry (cf. Table 1 and references [12] [13] [14] [15] [16] [17] [18] . So far, some additional marker candidates were found that, however, require further validation steps by generating testable hypotheses regarding their biochemical role in health and disease. The most notable hallmark secondary candidates are C16:1 and C4DC for PKU, C4DC for GA-I, and C18:1 for MCADD. For the latter, C18:1, a biochemical explanation was already mentioned in the Results section. A validation of the not disease-specific marker candidates (fourth category) seems to be delicate because some are prioritized as secondary or even primary markers according to our categorization. In particular, the highly scored amino acids ARG and GLU cannot be confirmed by the diseases' primary metabolic reactions. However, this last step of biomarker discovery is inevitable and emphasizes, for example, the development of bioassays or preclinical models to confirm the bioanalytical measurements to initiate future marker validation. 9, 10 To assess the diagnostic power of identified marker candidates, we tested several classifiers. Our experimental results for MMA indicated sensitivities between 88% and 98%, PPV ranged between 68.6% and 98%, depending on the applied classifier and marker subset. All other diseases achieved comparable classification results compared to MMA; the best overall classification accuracy yielded a 3-layer neural network. In newborn screening, disease classification is targeted to achieve sensitivities close to 100% and PPV significantly above 50% to reduce subsequent diagnostic procedures, which cause additional efforts and costs. 36, 37 Because our research data comprise newborn screening data of not standardized date of sampling-the influence of nutrition or early treatments was not clearly assessable-the classifiers'accuracy is definitely underestimated as expected in this context. Our results may reflect the constitution of provided research data, but they certainly do not obscure the novelty of our methodological approach to identify metabolic markers. Alternatively to the popular machinelearning approach for disease classification, we presented a retrieval technique that combines the tasks of biomarker identification and similarity query processing to classify abnormal metabolic profiles directly from DB requests. We introduced a similarity measure based on BMI score weights, which is the base to match MS data with high accuracy.
The presented methodology has great potential for the development of automated diagnostics, taking neither a priori nor expert knowledge into account. After reviewing a certain population of healthy and diseased patients, the proposed procedure can identify marker candidates that have significant variance from a normal profile and thus can become diagnostic of a given disease. By huge advances in high-throughput technologies in the past years, a wide set of the human metabolome is already generable so that not previously discovered markers can be identified from MS data using appropriate data-mining techniques. 38 These findings can enlarge the known marker spectrum of a disease significantly, which in turn further enhances the sensitivity of diagnostic testing. Therefore, measuring and mining the biochemical state of diseased people as well as drug monitoring of patients with a known disease are very relevant to understanding how diseases manifest and drugs act. Powerful bioinformatics and data-mining methods such as BMI are helpful tools that contribute to the challenging biomarker discovery process.
In conclusion, we delineated a new approach to discover biomarkers consisting of identification and prioritization of marker candidates, as well as disease classification that contributes to a better understanding of biochemical roles of metabolites during health and disease. Our experimental results confirmed all known markers of several disturbances of newborn metabolism and revealed a number of marker candidates, which have the potential to become novel diagnostic markers urgently needed for disease screening and early diagnostics.
